Identification of CD4+CD25+CD127‑ regulatory T cells and CD14+HLA‑DR‑/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer

Wang,Jinhu; Yang,Jianhong

doi:10.3892/br.2016.694

Identification of CD4+CD25+CD127‑ regulatory T cells and CD14+HLA‑DR‑/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer

Authors:
- Jinhu Wang
- Jianhong Yang
View Affiliations

Affiliations: Department of Laboratory Medicine, Taicang Affiliated Hospital of Soochow University, Taicang, Jiangsu 215400, P.R. China
Published online on: May 27, 2016 https://doi.org/10.3892/br.2016.694
Pages: 208-212

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to identify cluster of differentiation 4+ (CD4+)CD25+CD127‑ regulatory T cells (Tregs) and CD14+ human leukocyte antigen‑antigen D‑related (HLA‑DR‑)/low myeloid‑derived suppressor cells (MDSCs) in patients with breast cancer of varying stages, and investigate their roles and the potential interactions in the prognosis of breast cancer. A total of 40 patients with breast cancer were included in the study. A total of 30 healthy individuals served as the healthy control. Flow cytometry was performed for the identification of biomarkers. Natural Tregs were characterized by the expression of CD4+CD25+CD127‑. The MDSC frequency was expressed as the percentage of CD33+CD11b+HLA‑DR‑lineage markers (Lin)‑. The absolute number of Tregs was higher in breast cancer patients compared to the healthy control. The absolute number of Tregs in the patients with stage III or IV breast cancer was higher than those of the stage I or II, respectively. The percentage showed a gradual increase in the patients with breast cancer compared with the normal control. No direct correlation was established between the number or percentage of Tregs and the patient survival. There was a higher percentage of circulating MDSCs in breast cancer patients compared with the normal individuals. A close correlation was established between clinical cancer stage and percentage and total number of circulating MDSCs. To be exact, a significant increase of MDSC percentage and total number was observed in patients with stage III‑IV breast cancer compared with the other cancer patients (stage I‑II) and the normal individuals. No statistical difference was observed in the 3‑ and 5‑year survival rates in the breast cancer patients with enhanced expression of Tregs, compared with the normal individuals. In conclusion, enhanced expression of CD4+CD25+CD127‑ Tregs cells and CD33+CD11+HLA‑DR‑LIN‑ MDSCs were identified from patients with breast cancer. Patients with advanced stage breast cancer showed upregulation of such cells. However, these 2 types of cells showed no correlation with the prognosis of breast cancer.

View Figures

View References

1	Forrest AP, Stewart HJ, Everington D, Prescott RJ, McArdle CS, Harnett AN, Smith DC and George WD: Scottish Cancer Trials Breast Group: Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet. 348:708–713. 1996. View Article : Google Scholar : PubMed/NCBI
2	Stewart BW and Kleihues P: World cancer report. International Agency for Research on Cancer. IARC Press. (Lyon). 2003.
3	Mehta P: Potential role of platelets in the pathogenesis of tumor metastasis. Blood. 63:55–63. 1984.PubMed/NCBI
4	Gilboa E: The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol. 2:789–792. 2001. View Article : Google Scholar : PubMed/NCBI
5	Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H and Fujii H: Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer. 98:148–153. 2008. View Article : Google Scholar : PubMed/NCBI
6	Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG and Levings MK: Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 19:345–354. 2007. View Article : Google Scholar : PubMed/NCBI
7	Hezova R, Slaby O, Faltejskova P, Mikulkova Z, Buresova I, Raja KR, Hodek J, Ovesna J and Michalek J: MicroRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol. 260:70–74. 2010. View Article : Google Scholar : PubMed/NCBI
8	Nagaraj S and Gabrilovich DI: Myeloid-derived suppressor cells. Adv Exp Med Biol. 601:213–223. 2007. View Article : Google Scholar : PubMed/NCBI
9	Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ and Ostrand-Rosenberg S: Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother. 57:1493–1504. 2008. View Article : Google Scholar : PubMed/NCBI
10	Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ and Montero AJ: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 58:49–59. 2009. View Article : Google Scholar : PubMed/NCBI
11	Poschke I, Mougiakakos D, Hansson J, Masucci GV and Kiessling R: Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 70:4335–4345. 2010. View Article : Google Scholar : PubMed/NCBI
12	Adegboyega TO, Landercasper J, Linebarger JH, et al: Institutional review of compliance with NCCN guidelines for breast cancer: Lessons learned from real-time multidimensional synoptic reporting. J Natl Compr Canc Netw. 13:177–183. 2015.PubMed/NCBI
13	Ulmer AJ, Scholz W, Ernst M, Brandt E and Flad HD: Isolation and subfractionation of human peripheral blood mononuclear cells (PBMC) by density gradient centrifugation on Percoll. Immunobiology. 166:238–250. 1984. View Article : Google Scholar : PubMed/NCBI
14	Lyons AB and Parish CR: Determination of lymphocyte division by flow cytometry. J Immunol Methods. 171:131–137. 1994. View Article : Google Scholar : PubMed/NCBI
15	Nagaraj S and Gabrilovich DI: Myeloid-derived suppressor cells in human cancer. Cancer J. 16:348–353. 2010. View Article : Google Scholar : PubMed/NCBI
16	Filipazzi P, Huber V and Rivoltini L: Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 61:255–263. 2012. View Article : Google Scholar : PubMed/NCBI
17	Wang L, Chang EWY, Wong SC, Ong S-M, Chong DQ and Ling KL: Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 190:794–804. 2013. View Article : Google Scholar : PubMed/NCBI
18	Mohapatra SS, Bharadwaj SN and Mohapatra S: Compositions and methods for modulating myeloid derived suppressor cells. US Patent 20140336239 A1. Filed December 3, 2011; issued November 13. 2014.
19	Lindau D, Gielen P, Kroesen M, Wesseling P and Adema GJ: The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 138:105–115. 2013. View Article : Google Scholar : PubMed/NCBI
20	Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME and Rosenberg SA: Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res. 18:5212–5223. 2012. View Article : Google Scholar : PubMed/NCBI
21	Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, Woo T and Epstein AL: Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med. 9:902011. View Article : Google Scholar : PubMed/NCBI
22	Sakaguchi S: Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 6:345–352. 2005. View Article : Google Scholar : PubMed/NCBI
23	Ramsdell F: Foxp3 and natural regulatory T cells: Key to a cell lineage? Immunity. 19:165–168. 2003. View Article : Google Scholar : PubMed/NCBI
24	Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, Zhu J, Wei H and Zhao K: Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One. 8:e571142013. View Article : Google Scholar : PubMed/NCBI
25	Hein F, Massin F, Cravoisy-Popovic A, Barraud D, Levy B, Bollaert PE and Gibot S: The relationship between CD4+CD25+CD127- regulatory T cells and inflammatory response and outcome during shock states. Crit Care. 14:R192010. View Article : Google Scholar : PubMed/NCBI
26	Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, de Fazekas St Groth B, et al: CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 203:1701–1711. 2006. View Article : Google Scholar : PubMed/NCBI